Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 558

1.

Imaging and T Category for Prostate Cancer in the 8th Edition of the Union for International Cancer Control TNM Classification.

van der Poel H, van der Kwast T, Aben K, Mottet N, Mason M.

Eur Urol Oncol. 2019 Jul 12. pii: S2588-9311(19)30076-8. doi: 10.1016/j.euo.2019.06.001. [Epub ahead of print] No abstract available.

PMID:
31307959
2.

Validation of the prognostic value of NF-κB p65 in prostate cancer: A retrospective study using a large multi-institutional cohort of the Canadian Prostate Cancer Biomarker Network.

Grosset AA, Ouellet V, Caron C, Fragoso G, Barrès V, Delvoye N, Latour M, Aprikian A, Bergeron A, Chevalier S, Fazli L, Fleshner N, Gleave M, Karakiewicz P, Lacombe L, Lattouf JB, van der Kwast T, Trudel D, Mes-Masson AM, Saad F; Canadian Prostate Cancer Biomarker Network.

PLoS Med. 2019 Jul 2;16(7):e1002847. doi: 10.1371/journal.pmed.1002847. eCollection 2019 Jul.

3.

Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations.

Van den Broeck T, van den Bergh RCN, Briers E, Cornford P, Cumberbatch M, Tilki D, De Santis M, Fanti S, Fossati N, Gillessen S, Grummet JP, Henry AM, Lardas M, Liew M, Mason M, Moris L, Schoots IG, van der Kwast T, van der Poel H, Wiegel T, Willemse PM, Rouvière O, Lam TB, Mottet N.

Eur Urol Focus. 2019 Jun 24. pii: S2405-4569(19)30159-2. doi: 10.1016/j.euf.2019.06.004. [Epub ahead of print]

PMID:
31248850
4.

Consistent Biopsy Quality and Gleason Grading Within the Global Active Surveillance Global Action Plan 3 Initiative: A Prerequisite for Future Studies.

van der Kwast TH, Helleman J, Nieboer D, Bruinsma SM, Roobol MJ; Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance GAP3 Consortium.

Eur Urol Oncol. 2019 May;2(3):333-336. doi: 10.1016/j.euo.2018.08.017. Epub 2018 Sep 13.

PMID:
31200849
5.

GBX2 Methylation Is a Novel Prognostic Biomarker and Improves Prediction of Biochemical Recurrence Among Patients with Prostate Cancer Negative for Intraductal Carcinoma and Cribriform Architecture.

Jeyapala R, Savio AJ, Olkhov-Mitsel E, Kamdar S, Zhao F, Cuizon C, Liu RSC, Zlotta A, Fleshner N, van der Kwast T, Bapat B.

Eur Urol Oncol. 2019 May;2(3):231-238. doi: 10.1016/j.euo.2018.08.003. Epub 2018 Sep 1.

PMID:
31200836
6.

Data Set for the Reporting of Carcinoma of the Renal Pelvis and Ureter-Nephroureterectomy and Ureterectomy Specimens: Recommendations From the International Collaboration on Cancer Reporting (ICCR).

Samaratunga H, Judge M, Delahunt B, Srigley J, Brimo F, Comperat E, Koch M, Lopez-Beltran A, Reuter V, Shanks J, Tsuzuki T, van der Kwast T, Varma M, Grignon D.

Am J Surg Pathol. 2019 Jun 11. doi: 10.1097/PAS.0000000000001305. [Epub ahead of print]

PMID:
31192862
7.

Gleason grade patterns in nodal metastasis and corresponding prostatectomy specimens: impact on patient outcome.

Downes MR, Xu B, van der Kwast TH.

Histopathology. 2019 Jun 8. doi: 10.1111/his.13938. [Epub ahead of print]

PMID:
31177561
8.

Grading Noninvasive Bladder Cancer: World Health Organisation 1973 or 2004 May Be the Wrong Question.

Varma M, Delahunt B, van der Kwast T.

Eur Urol. 2019 May 10. pii: S0302-2838(19)30362-8. doi: 10.1016/j.eururo.2019.05.001. [Epub ahead of print]

PMID:
31080126
9.
10.

An actionable sterol-regulated feedback loop modulates statin sensitivity in prostate cancer.

Longo J, Mullen PJ, Yu R, van Leeuwen JE, Masoomian M, Woon DTS, Wang Y, Chen EX, Hamilton RJ, Sweet JM, van der Kwast TH, Fleshner NE, Penn LZ.

Mol Metab. 2019 Jul;25:119-130. doi: 10.1016/j.molmet.2019.04.003. Epub 2019 Apr 10.

11.

Dataset for reporting of carcinoma of the urethra (in urethrectomy specimens): recommendations from the International Collaboration on Cancer Reporting (ICCR).

Shanks JH, Srigley JR, Brimo F, Comperat E, Delahunt B, Koch M, Lopez-Beltran A, Reuter VE, Samaratunga H, Tsuzuki T, van der Kwast T, Varma M, Grignon D.

Histopathology. 2019 Apr 22. doi: 10.1111/his.13877. [Epub ahead of print] Review.

PMID:
31009090
12.

Long-term oncological outcomes of patients with paratesticular sarcoma.

Goldberg H, Wong LM, Dickson B, Catton C, Yap SA, Alkasab T, Evans A, van der Kwast T, Jewett MAS, Hamilton RJ.

BJU Int. 2019 Apr 18. doi: 10.1111/bju.14775. [Epub ahead of print]

PMID:
31001920
13.

Extraprostatic Extension in Core Biopsies Epitomizes High-risk but Locally Treatable Prostate Cancer.

Goldberg H, Ramiz AH, Glicksman R, Salgado NS, Chandrasekar T, Klaassen Z, Wallis CJD, Hosni A, Moraes FY, Ghai S, Kulkarni GS, Hamilton RJ, Perlis N, Toi A, Chung P, Evans A, van der Kwast T, Finelli A, Fleshner N, Berlin A.

Eur Urol Oncol. 2019 Feb;2(1):88-96. doi: 10.1016/j.euo.2018.05.003. Epub 2018 May 27.

PMID:
30929849
14.

Exploring targets of TET2-mediated methylation reprogramming as potential discriminators of prostate cancer progression.

Kamdar S, Isserlin R, Van der Kwast T, Zlotta AR, Bader GD, Fleshner NE, Bapat B.

Clin Epigenetics. 2019 Mar 27;11(1):54. doi: 10.1186/s13148-019-0651-z.

15.

The Proteogenomic Landscape of Curable Prostate Cancer.

Sinha A, Huang V, Livingstone J, Wang J, Fox NS, Kurganovs N, Ignatchenko V, Fritsch K, Donmez N, Heisler LE, Shiah YJ, Yao CQ, Alfaro JA, Volik S, Lapuk A, Fraser M, Kron K, Murison A, Lupien M, Sahinalp C, Collins CC, Tetu B, Masoomian M, Berman DM, van der Kwast T, Bristow RG, Kislinger T, Boutros PC.

Cancer Cell. 2019 Mar 18;35(3):414-427.e6. doi: 10.1016/j.ccell.2019.02.005.

PMID:
30889379
16.

A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer.

Hugosson J, Roobol MJ, Månsson M, Tammela TLJ, Zappa M, Nelen V, Kwiatkowski M, Lujan M, Carlsson SV, Talala KM, Lilja H, Denis LJ, Recker F, Paez A, Puliti D, Villers A, Rebillard X, Kilpeläinen TP, Stenman UH, Godtman RA, Stinesen Kollberg K, Moss SM, Kujala P, Taari K, Huber A, van der Kwast T, Heijnsdijk EA, Bangma C, De Koning HJ, Schröder FH, Auvinen A; ERSPC investigators.

Eur Urol. 2019 Jul;76(1):43-51. doi: 10.1016/j.eururo.2019.02.009. Epub 2019 Feb 26.

PMID:
30824296
17.

Canadian Urological Association guideline: Muscle-invasive bladder cancer.

Kulkarni GS, Black PC, Sridhar SS, Kapoor A, Zlotta AR, Shayegan B, Rendon R, Chung P, Van Der Kwast T, Alimohamed N, Fradet Y, Kassouf W.

Can Urol Assoc J. 2019 Jan 31. doi: 10.5489/cuaj.5902. [Epub ahead of print] No abstract available.

PMID:
30763236
18.

Are there differences between de novo and secondary upper tract urothelial carcinoma tumours?

Goldberg H, Cheung DC, Chandrasekar T, Klaassen Z, Wallis CJD, Kulkarni GS, Sayyid R, Evans A, Masoomian M, Bapat B, Van Der Kwast T, Hamilton RJ, Zlotta A, Fleshner N.

Can Urol Assoc J. 2019 Jan 21. doi: 10.5489/cuaj.5595. [Epub ahead of print]

PMID:
30763230
19.

Accuracy of renal tumour biopsy for the diagnosis and subtyping of papillary renal cell carcinoma: analysis of paired biopsy and nephrectomy specimens with focus on discordant cases.

Prendeville S, Richard PO, Jewett MAS, Kachura JR, Sweet JM, van der Kwast TH, Cheung CC, Finelli A, Evans AJ.

J Clin Pathol. 2019 May;72(5):363-367. doi: 10.1136/jclinpath-2018-205655. Epub 2019 Feb 12.

PMID:
30755496
20.

Widespread and Functional RNA Circularization in Localized Prostate Cancer.

Chen S, Huang V, Xu X, Livingstone J, Soares F, Jeon J, Zeng Y, Hua JT, Petricca J, Guo H, Wang M, Yousif F, Zhang Y, Donmez N, Ahmed M, Volik S, Lapuk A, Chua MLK, Heisler LE, Foucal A, Fox NS, Fraser M, Bhandari V, Shiah YJ, Guan J, Li J, Orain M, Picard V, Hovington H, Bergeron A, Lacombe L, Fradet Y, Têtu B, Liu S, Feng F, Wu X, Shao YW, Komor MA, Sahinalp C, Collins C, Hoogstrate Y, de Jong M, Fijneman RJA, Fei T, Jenster G, van der Kwast T, Bristow RG, Boutros PC, He HH.

Cell. 2019 Feb 7;176(4):831-843.e22. doi: 10.1016/j.cell.2019.01.025.

PMID:
30735634
21.

ONECUT2 is a driver of neuroendocrine prostate cancer.

Guo H, Ci X, Ahmed M, Hua JT, Soares F, Lin D, Puca L, Vosoughi A, Xue H, Li E, Su P, Chen S, Nguyen T, Liang Y, Zhang Y, Xu X, Xu J, Sheahan AV, Ba-Alawi W, Zhang S, Mahamud O, Vellanki RN, Gleave M, Bristow RG, Haibe-Kains B, Poirier JT, Rudin CM, Tsao MS, Wouters BG, Fazli L, Feng FY, Ellis L, van der Kwast T, Berlin A, Koritzinsky M, Boutros PC, Zoubeidi A, Beltran H, Wang Y, He HH.

Nat Commun. 2019 Jan 17;10(1):278. doi: 10.1038/s41467-018-08133-6.

22.

Molecular landmarks of tumor hypoxia across cancer types.

Bhandari V, Hoey C, Liu LY, Lalonde E, Ray J, Livingstone J, Lesurf R, Shiah YJ, Vujcic T, Huang X, Espiritu SMG, Heisler LE, Yousif F, Huang V, Yamaguchi TN, Yao CQ, Sabelnykova VY, Fraser M, Chua MLK, van der Kwast T, Liu SK, Boutros PC, Bristow RG.

Nat Genet. 2019 Feb;51(2):308-318. doi: 10.1038/s41588-018-0318-2. Epub 2019 Jan 14.

PMID:
30643250
23.

A Phase 1 Pilot Study of Preoperative Radiation Therapy for Prostate Cancer: Long-Term Toxicity and Oncologic Outcomes.

Glicksman R, Sanmamed N, Thoms J, Zlotta AR, Finelli A, van der Kwast T, Sweet J, Jewett M, Klotz LH, Rosewall T, Fleshner NE, Bristow RG, Warde P, Berlin A.

Int J Radiat Oncol Biol Phys. 2019 May 1;104(1):61-66. doi: 10.1016/j.ijrobp.2018.12.054. Epub 2019 Jan 6.

PMID:
30625410
24.

Handling and reporting of pelvic lymphadenectomy specimens in prostate and bladder cancer: a web-based survey by the European Network of Uropathology.

Prendeville S, Berney DM, Bubendorf L, Compérat E, Egevad L, Hes O, Kristiansen G, Oxley J, van Leenders GJLH, Varma M, van der Kwast T.

Histopathology. 2019 May;74(6):844-852. doi: 10.1111/his.13818. Epub 2019 Apr 1.

PMID:
30604878
25.

Grading of prostate cancer: a work in progress.

Kweldam CF, van Leenders GJ, van der Kwast T.

Histopathology. 2019 Jan;74(1):146-160. doi: 10.1111/his.13767. Review.

PMID:
30565302
26.

Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore.

Verbeek JFM, Bangma CH, Kweldam CF, van der Kwast TH, Kümmerlin IP, van Leenders GJLH, Roobol MJ.

Urol Oncol. 2019 Feb;37(2):138-144. doi: 10.1016/j.urolonc.2018.11.021. Epub 2018 Dec 7.

PMID:
30528698
27.

Evolving concepts in prostatic neuroendocrine manifestations: from focal divergent differentiation to amphicrine carcinoma.

Bellur S, Van der Kwast T, Mete O.

Hum Pathol. 2019 Mar;85:313-327. doi: 10.1016/j.humpath.2018.11.016. Epub 2018 Nov 24.

PMID:
30481509
28.

Study Protocol for the DETECTIVE Study: An International Collaborative Study To Develop Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer.

Lam TBL, MacLennan S, Plass K, Willemse PM, Mason MD, Cornford P, Donaldson J, Davis NF, Dell'Oglio P, Fankhauser C, Grivas N, Ingels A, Lardas M, Liew M, Pang KH, Paterson C, Omar MI, Zattoni F, Buddingh KT, Van den Broeck T, Cumberbatch MG, Fossati N, Gross T, Moris L, Schoots IG, van den Bergh RCN, Briers E, Fanti S, De Santis M, Gillessen S, Grummet JP, Henry AM, van der Poel HG, van der Kwast TH, Rouvière O, Tilki D, Wiegel T, N'Dow J, Van Poppel H, Mottet N.

Eur Urol. 2019 Apr;75(4):699-702. doi: 10.1016/j.eururo.2018.11.009. Epub 2018 Nov 22. No abstract available.

PMID:
30473433
29.

Results of Prostate Cancer Screening in a Unique Cohort at 19yr of Follow-up.

Osses DF, Remmers S, Schröder FH, van der Kwast T, Roobol MJ.

Eur Urol. 2019 Mar;75(3):374-377. doi: 10.1016/j.eururo.2018.10.053. Epub 2018 Nov 9.

PMID:
30420254
30.

Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review.

Van den Broeck T, van den Bergh RCN, Arfi N, Gross T, Moris L, Briers E, Cumberbatch M, De Santis M, Tilki D, Fanti S, Fossati N, Gillessen S, Grummet JP, Henry AM, Lardas M, Liew M, Rouvière O, Pecanka J, Mason MD, Schoots IG, van Der Kwast TH, van Der Poel HG, Wiegel T, Willemse PM, Yuan Y, Lam TB, Cornford P, Mottet N.

Eur Urol. 2019 Jun;75(6):967-987. doi: 10.1016/j.eururo.2018.10.011. Epub 2018 Oct 17. Review.

PMID:
30342843
31.

SIU-ICUD on bladder cancer: pathology.

Compérat E, Babjuk M, Algaba F, Amin M, Brimo F, Grignon D, Hansel D, Hes O, Malavaud B, Reuter V, van der Kwast T.

World J Urol. 2019 Jan;37(1):41-50. doi: 10.1007/s00345-018-2466-5. Epub 2018 Sep 14.

PMID:
30218308
32.

The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation.

Ouellet V, Aprikian A, Bergeron A, Brimo F, Bristow RG, Chevalier S, Drachenberg D, Fazli L, Fleshner NE, Gleave M, Karakiewicz P, Klotz L, Lacombe L, Lattouf JB, van der Kwast T, Squire JA, Latour M, Trudel D, Mes-Masson AM, Saad F.

BMC Urol. 2018 Sep 10;18(1):78. doi: 10.1186/s12894-018-0392-x.

33.

Genomic Classifier for Guiding Treatment of Intermediate-Risk Prostate Cancers to Dose-Escalated Image Guided Radiation Therapy Without Hormone Therapy.

Berlin A, Murgic J, Hosni A, Pintilie M, Salcedo A, Fraser M, Kamel-Reid S, Zhang J, Wang Q, Ch'ng C, Deheshi S, Davicioni E, van der Kwast T, Boutros PC, Bristow RG, Chua MLK.

Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):84-91. doi: 10.1016/j.ijrobp.2018.08.030. Epub 2018 Aug 29.

34.

Concordance of biopsy and prostatectomy diagnosis of intraductal and cribriform carcinoma in a prospectively collected data set.

Masoomian M, Downes MR, Sweet J, Cheung C, Evans AJ, Fleshner N, Maganti M, Van der Kwast T.

Histopathology. 2019 Feb;74(3):474-482. doi: 10.1111/his.13747. Epub 2018 Nov 4.

PMID:
30160779
35.

A feed forward loop enforces YAP/TAZ signaling during tumorigenesis.

Gill MK, Christova T, Zhang YY, Gregorieff A, Zhang L, Narimatsu M, Song S, Xiong S, Couzens AL, Tong J, Krieger JR, Moran MF, Zlotta AR, van der Kwast TH, Gingras AC, Sicheri F, Wrana JL, Attisano L.

Nat Commun. 2018 Aug 29;9(1):3510. doi: 10.1038/s41467-018-05939-2.

36.

Risk SNP-Mediated Promoter-Enhancer Switching Drives Prostate Cancer through lncRNA PCAT19.

Hua JT, Ahmed M, Guo H, Zhang Y, Chen S, Soares F, Lu J, Zhou S, Wang M, Li H, Larson NB, McDonnell SK, Patel PS, Liang Y, Yao CQ, van der Kwast T, Lupien M, Feng FY, Zoubeidi A, Tsao MS, Thibodeau SN, Boutros PC, He HH.

Cell. 2018 Jul 26;174(3):564-575.e18. doi: 10.1016/j.cell.2018.06.014. Epub 2018 Jul 19.

PMID:
30033362
37.

Active Surveillance Magnetic Resonance Imaging Study (ASIST): Results of a Randomized Multicenter Prospective Trial.

Klotz L, Loblaw A, Sugar L, Moussa M, Berman DM, Van der Kwast T, Vesprini D, Milot L, Kebabdjian M, Fleshner N, Ghai S, Chin J, Pond GR, Haider M.

Eur Urol. 2019 Feb;75(2):300-309. doi: 10.1016/j.eururo.2018.06.025. Epub 2018 Jul 13.

PMID:
30017404
38.

Metric substage according to micro and extensive lamina propria invasion improves prognostics in T1 bladder cancer.

Fransen van de Putte EE, Otto W, Hartmann A, Bertz S, Mayr R, Bründl J, Breyer J, Manach Q, Compérat EM, Boormans JL, Bosschieter J, Jewett MAS, Stoehr R, van Leenders GJLH, Nieuwenhuijzen JA, Zlotta AR, Hendricksen K, Rouprêt M, Burger M, van der Kwast TH, van Rhijn BWG.

Urol Oncol. 2018 Aug;36(8):361.e7-361.e13. doi: 10.1016/j.urolonc.2018.05.007. Epub 2018 Jun 5.

PMID:
29880460
39.

Evaluation of an Aggressive Prostate Biopsy Strategy in Men Younger than 50 Years.

Goldberg H, Klaassen Z, Chandrasekar T, Wallis CJD, Toi A, Sayyid R, Bhindi B, Nesbitt M, Evans A, van der Kwast T, Sweet J, Perlis N, Hamilton RJ, Kulkarni GS, Finelli A, Zlotta A, Fleshner N.

J Urol. 2018 Nov;200(5):1056-1061. doi: 10.1016/j.juro.2018.05.017. Epub 2018 Jul 27.

PMID:
29758220
40.

Magnetic resonance guided focused high frequency ultrasound ablation for focal therapy in prostate cancer - phase 1 trial.

Ghai S, Perlis N, Lindner U, Hlasny E, Haider MA, Finelli A, Zlotta AR, Kulkarni GS, van der Kwast TH, McCluskey SA, Kucharczyk W, Trachtenberg J.

Eur Radiol. 2018 Oct;28(10):4281-4287. doi: 10.1007/s00330-018-5409-z. Epub 2018 Apr 25.

PMID:
29696431
41.

The Evolutionary Landscape of Localized Prostate Cancers Drives Clinical Aggression.

Espiritu SMG, Liu LY, Rubanova Y, Bhandari V, Holgersen EM, Szyca LM, Fox NS, Chua MLK, Yamaguchi TN, Heisler LE, Livingstone J, Wintersinger J, Yousif F, Lalonde E, Rouette A, Salcedo A, Houlahan KE, Li CH, Huang V, Fraser M, van der Kwast T, Morris QD, Bristow RG, Boutros PC.

Cell. 2018 May 3;173(4):1003-1013.e15. doi: 10.1016/j.cell.2018.03.029. Epub 2018 Apr 19.

42.

The World Health Organization 1973 classification system for grade is an important prognosticator in T1 non-muscle-invasive bladder cancer.

van de Putte EEF, Bosschieter J, van der Kwast TH, Bertz S, Denzinger S, Manach Q, Compérat EM, Boormans JL, Jewett MAS, Stoehr R, van Leenders GJLH, Nieuwenhuijzen JA, Zlotta AR, Hendricksen K, Rouprêt M, Otto W, Burger M, Hartmann A, van Rhijn BWG.

BJU Int. 2018 Dec;122(6):978-985. doi: 10.1111/bju.14238. Epub 2018 Apr 27.

PMID:
29637669
43.

On cribriform prostate cancer.

Kweldam CF, van der Kwast T, van Leenders GJ.

Transl Androl Urol. 2018 Feb;7(1):145-154. doi: 10.21037/tau.2017.12.33. Review.

44.

Editorial Comment.

van der Kwast TH.

J Urol. 2018 Jun;199(6):1509. doi: 10.1016/j.juro.2017.12.079. Epub 2018 Mar 12. No abstract available.

PMID:
29545188
45.

The mTOR Targets 4E-BP1/2 Restrain Tumor Growth and Promote Hypoxia Tolerance in PTEN-driven Prostate Cancer.

Ding M, Van der Kwast TH, Vellanki RN, Foltz WD, McKee TD, Sonenberg N, Pandolfi PP, Koritzinsky M, Wouters BG.

Mol Cancer Res. 2018 Apr;16(4):682-695. doi: 10.1158/1541-7786.MCR-17-0696. Epub 2018 Feb 16.

46.

Role of Magnetic Resonance Imaging Targeted Biopsy in Detection of Prostate Cancer Harboring Adverse Pathological Features of Intraductal Carcinoma and Invasive Cribriform Carcinoma.

Prendeville S, Gertner M, Maganti M, Pintilie M, Perlis N, Toi A, Evans AJ, Finelli A, van der Kwast TH, Ghai S.

J Urol. 2018 Jul;200(1):104-113. doi: 10.1016/j.juro.2018.01.081. Epub 2018 Feb 2.

PMID:
29408568
47.

Utility of Pathology Imagebase for standardisation of prostate cancer grading.

Egevad L, Delahunt B, Berney DM, Bostwick DG, Cheville J, Comperat E, Evans AJ, Fine SW, Grignon DJ, Humphrey PA, Hörnblad J, Iczkowski KA, Kench JG, Kristiansen G, Leite KRM, Magi-Galluzzi C, McKenney JK, Oxley J, Pan CC, Samaratunga H, Srigley JR, Takahashi H, True LD, Tsuzuki T, van der Kwast T, Varma M, Zhou M, Clements M.

Histopathology. 2018 Jul;73(1):8-18. doi: 10.1111/his.13471. Epub 2018 Mar 5.

PMID:
29359484
48.

Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations.

Böttcher R, Kweldam CF, Livingstone J, Lalonde E, Yamaguchi TN, Huang V, Yousif F, Fraser M, Bristow RG, van der Kwast T, Boutros PC, Jenster G, van Leenders GJLH.

BMC Cancer. 2018 Jan 2;18(1):8. doi: 10.1186/s12885-017-3976-z.

49.

Suspicious findings on micro-ultrasound imaging and early detection of prostate cancer.

Ghai S, Van der Kwast T.

Urol Case Rep. 2017 Nov 21;16:98-100. doi: 10.1016/j.eucr.2017.11.013. eCollection 2018 Jan.

50.

Characteristics and outcome of prostate cancer patients with overall biopsy Gleason score 3 + 4 = 7 and highest Gleason score 3 + 4 = 7 or > 3 + 4 = 7.

Verhoef EI, Kweldam CF, Kümmerlin IP, Nieboer D, Bangma CH, Incrocci L, van der Kwast TH, Roobol MJ, van Leenders GJ.

Histopathology. 2018 Apr;72(5):760-765. doi: 10.1111/his.13427. Epub 2018 Jan 14.

PMID:
29094386

Supplemental Content

Loading ...
Support Center